# Affimed

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/affimed

- Industry: Biotechnology
- Headquarters: Mannheim, Germany
- Website: www.affimed.com
- Total disclosed funding: $97M
- Latest round: Series E (Jul 14, 2014)
- Investors on record: 9

## About

Based in Heidelberg, Germany, and founded in 2000 by Melvyn Little, Affimed GmbH is a biopharmaceutical company engaged in developing unique antibody formats for the treatment of cancer, such as hematological and solid tumors as well as for inflammatory diseases. In January 2021, Affimed GmbH raised EUR 25 million in venture debt funding from Silicon Valley Bank. The company trades on Nasdaq under the ticker symbol AFMD. As of November 2021, Affimed GmbH employees approximately 153 employees and Adi Hoess is the CEO of the company.

Affimed GmbH develops multiple innate cell engagers, such as AFM13, AFM13 + Adoptive NK cells, AFM13 + ANTI-PD-1, AFM24, AFM24 + Adoptive NK cells, AFM24 + ANTI-PD-L1, AFM28, AFM32, Genentech, and ICE+ NK cell combination. AFM13 is ICE® (innate cell engager) molecule that benefits patients with CD30+ lymphomas. AFM24 is an EGFR-binding ICE® (innate cell engager) molecule that kills EGFR-expressing tumors. In addition, the company’s technology comprises ROCK® (redirected optimized cell-killing) platform that allows a molecular approach to generate customizable ICE® molecules.

Affimed GmbH has generated total revenue of EUR 28.360 million in the fiscal year ended in December 2020.

Affimed GmbH plans to use its proceeds from January 2021 funding to support the broad development strategy of its products.

## Funding rounds

- Series E, Jul 14, 2014, $16M — OrbiMed Advisors, EQT Life Sciences, BioMed Partners, Novo Nordisk A/S, Aeris Capital
- Series D, Oct 8, 2012, $20M — OrbiMed Advisors, EQT Life Sciences, BioMed Partners, Novo Nordisk A/S, SGR Holdings, Aeris Capital
- Series C, Jun 23, 2010, $25M — OrbiMed Advisors, EQT Life Sciences, BioMed Partners, Novo Nordisk A/S, Aeris Capital, Caduceus Capital Partners
- Series B, Mar 27, 2007, $33M — OrbiMed Advisors, First Ventury, EQT Life Sciences, BioMed Partners, Aeris Capital, Caduceus Capital Partners
- Series A, Apr 10, 2003, $2.2M — First Ventury, SHS Gesellschaft fur Beteiligungsmanagement

## Investors

- First Ventury (https://capitalatlas.ai/funds/first-ventury) — Series A, Series B
- SHS Gesellschaft fur Beteiligungsmanagement (https://capitalatlas.ai/funds/shs-gesellschaft-fur-beteiligungsmanagement) — Series A
- OrbiMed Advisors (https://capitalatlas.ai/funds/orbimed-advisors) — Series B, Series C, Series D, Series E
- EQT Life Sciences (https://capitalatlas.ai/funds/eqt-life-sciences) — Series B, Series C, Series D, Series E
- BioMed Partners (https://capitalatlas.ai/funds/biomed-partners) — Series B, Series C, Series D, Series E
- Aeris Capital — Series B, Series C, Series D, Series E
- Caduceus Capital Partners (https://capitalatlas.ai/funds/caduceus-capital-partners) — Series B, Series C
- Novo Nordisk A/S — Series C, Series D, Series E
- SGR Holdings — Series D